References
- Nilius B, Schuttler K, Benndorf K, Boldt W. Electrophysiological effects of the new antiarrhythmic compound Bonnecor® on mammalian myocardium. Pharmazie 1985; 40: 847–51
- Rostock KJ, Rathgen K, Rostock G, Volkmann G, Pfeiffer D. Klinische Wirksamkeit von Bonnecor® bei oraler Langzeitgabe. Medicamentum 1990; 31: 53–7
- Volkmann H, Rostock KJ. Klinische Wirksamkeit von Tiracizin bei intravenöser Applikation. Medicamentum 1990; 31: 26–9
- Volkmann H, Kuhnert H, Dannberg G, Heinke M, Leeder U, Popp U. Elektrophysiologische und antiar-rhythmische Effekte von Tiracizin bei ventrikulären Arrhythmien. Gesamte Inn Med 1992; 46: 635–41
- Rostock KJ, Rostock G. Pharmakokinetik von Tiracizin und seinen Metaboliten. Bonnecor® (Tiracizin) ein neues Antiarrhythmikum, KJ Rostock. Akademie Verlag, BerlinGermany 1992; 45–51
- Berndt A, Oertel R, Terhaag B, Richter K, Gramatté T. Pharmacokinetics of tiracizine-single dose and steady stale kinetics. Institute of Clinical Pharmacology, Medical Faculty, Technical University, DresdenGermany 1992, Internal Report
- Brosen K, Gram LF. Clinical significance of the sparteine debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537–47
- Berndt A, Oertel R, Terhaag B, Richter K, Gramatté T. Food enhances bioavailability of the new antiarrhythmic agent tiracizine by affecting its hepatic first pass metabolism: evidence by serum and urine metabolite kinetics. Am J Ther 1994; 1: 22–9
- Jainta H. Pharmakokinetics of Tiracizine in various animals. Martin Luther Universität Halle-Wittenberg, Biochemical Faculty, HalleGermany 1994, [Thesis]
- Ie Petit G. Die pH-abhängige Lipidlöslichkeit von Arzneistoffen. Pharmazie 1977; 32: 189–91
- Lemmer B. Chronopharmakokinetik. Chronopharmakologie. Tagesrhythmen und Arzneimittelwirkung. 2nd ed., B Lemmer. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, StuttgartGermany 1984; 57–70
- Berndt A, Oertel R, Richter K, Grammatt T. Lassen sich aus der Analyse der Serumund Urinkonzentrationsverläufe des Antiarrhythmikums Tiracizin Hinweise zu seinem Interaktionspotential ableiten. Klin Pharmakol Aktuell 1993; 4: 23
- Waterhouse JM, Minors DS. Temporal aspects of renal drug elimination. Chronopharmacology, B Lemmer. Marcel Dekker, New York 1989; 35–50
- Koren G, Ferrazzini G, Sohl H, Robieux I, Johnson D, Giesbrecht E. Chronopharmacology of methotrexate pharmacokinetics in childhood leukaemia. Chronobiol Int 1992; 9: 434–8
- le Petit G. Physicochemical properties of tiracizine. Institute of Clinical Pharmacology, Medical Faculty, Technical University, DresdenGermany 1992, Internal Report
- Fleck C, Schilder L, Schulze U, et al. Möglichkeiten zur Beschleunigiung der Elimination von Bonnecor®. Z Gesamte Inn Med 1990; 45: 604–9
- Milme MD, Scribner BH, Crawford MA. Non-ionic diffusion and the excretion of weak acids and bases. Am J Med 1958; 24: 709–29
- Kiddie MA, Kaye CM, Turner P, Shaw T DR. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol 1974; 1: 229–32
- Johnston A, Burgess CD, Warrington SJ, Wadsworth J, Hamer N AJ. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers. Br J Clin Pharmacol 1979; 8: 349–52
- Mitchell BG, Clements JA, Pottage A, Prescott LF. Mexiletine disposition: individual variation response to urine acidification and alkalisation. Br J Clin Pharmacol 1983; 16: 281–4
- Nilsson MI, Widerlöv E, Meresaar U, Anggard E. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982; 22: 337–42
- Widerlöv E, Termander B, Nilsson MI. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. Eur J Clin Pharmacol 1989; 37: 359–63
- Woosley RL. Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs. Am J Cardiol 1988; 62: 9H–7H
- Berndt A, Oertel R, Terhaag B, Richter K, Gramatté T. Relationships between pharmacokinetics and changes in the ECG in healthy volunteers for the antiarrhythmic agent tiracizine. Naunyn Schmiedebergs Arch Pharmacol 1993; 347(suppl)R27